IVI-RETRACT

IVI-RETRACT registry update: recruitment status and timeline revised

Trial at a glance

NCT
NCT07481500
Acronym
IVI-RETRACT
Sponsor
Jakkrit Juhong
Indication
Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema; Retinal Vein Occlusion; Intravitreal Injections; Polypoidal Choroidal Vasculopathy
Comparator
Eyelid Speculum (Group A)
Registered enrollment
129
Primary endpoints
Pain Perception — 1-5 minutes after intravitreal injection (Day 0); Procedure Duration — During intravitreal injection procedure (Day 0); Patient Satisfaction — 1-5 minutes after intravitreal injection (Day 0); Procedure-Related Complications — Day 0, Day 1, and Week 4 post-injection
Recruitment
Active, not recruiting
Primary completion
2026-10-07
Last registry update
2026-09-25
Results posted
No

What changed

Clinical trials

Registry updateRetina

IVI-RETRACT registry update: recruitment status and timeline revised

ClinicalTrials.gov lists IVI-RETRACT (NCT07481500), a randomized comparison of eyelid speculum and cotton-tipped applicator retraction for intravitreal injections, as active but no longer recruiting. Enrollment is now 129 actual participants, up from 120 estimated; estimated primary completion moved from June 2027 to 7 October 2026. No results are posted.

2 min
ClinicalTrials.gov ↗

Timeline

  1. IVI-RETRACT registry update: recruitment status and timeline revised

References